Extraction form for project: Screening for Glaucoma in Adults - 1 of 2

Design Details

1. Study design

Arms

Arm NameArm Description
A. Brimonidine 0.2% every 12 hours for 29 days
B. Placebo Fellow eye comparator

Sample Characteristics

1. N
A. Brimonidine 0.2% every 12 hours for 29 days
B. Placebo Fellow eye comparator
Total
2. Baseline population
A. Brimonidine 0.2% every 12 hours for 29 days
B. Placebo Fellow eye comparator
Total

Outcomes

TypeDomainSpecific measurement (i.e., tool/definition/specific outcome)PopulationsTimepoints
CategoricalVision disorderIOP percent reduction from baseline
  • All Participants
  • end of study

Risk of Bias Assessment

1. Random assignment
2. Allocation concealed
3. Groups similar at baseline
4. Eligibility criteria specified
5. Blinding: outcome assessors or data analysts
6. Intention-to-treat analysis
7. Reporting of attrition, contamination, etc.
8. Differential loss to followup or overall high loss to followup
9. Appropriate analysis including cluster correlation
10. Funding source
11. Randomization adequate?
12. Allocation concealment adequate?
13. Groups similar at baseline?
14. Eligibility criteria specified?
15. Outcome assessors masked?
16. Care provider masked?
17. Patient masked?
18. Attrition and withdrawals reported?
19. Loss to followup differential/ high?
20. People analyzed in the groups in which they were randomized?
21. Quality

Results

Categorical


Vision disorder (IOP percent reduction from baseline)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Brimonidine 0.2% every 12 hours for 29 days B. Placebo Fellow eye comparator
vs.
end of study
Percentage
p value
Within Arm ComparisonsNet Comparisons
A. Brimonidine 0.2% every 12 hours for 29 days B. Placebo Fellow eye comparator
vs.